Edition:
India

Sienna Biopharmaceuticals Inc (SNNA.OQ)

SNNA.OQ on NASDAQ Stock Exchange Global Select Market

9.74USD
20 Nov 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$9.74
Open
$9.69
Day's High
$9.95
Day's Low
$9.69
Volume
6,749
Avg. Vol
17,302
52-wk High
$25.58
52-wk Low
$9.01

Summary

Name Age Since Current Position

Frederick Beddingfield

52 President, Chief Executive Officer, Director

John Smither

65 2018 Chief Financial Officer

Majed Kheir

Vice President - Operations

Susan Lundeen

Vice President - Human Resources

Caroline Van Hove

2018 Chief Commercial Officer

James Hindman

57 2018 Director

Robert More

2016 Director

Biographies

Name Description

Frederick Beddingfield

Dr. Frederick C. Beddingfield III, M.D., Ph.D., is a President, Chief Executive Officer, Director of the Company. He is also a board-certified dermatologist and dermatologic surgeon. Dr. Beddingfield served as Chief Medical Officer of Kythera Biopharmaceuticals, Inc. from March, 2013 until it was acquired by Allergan in October, 2015. Prior to his appointment at Kythera, he held the role of Vice President and Therapeutic Area Head, Dermatology and Aesthetics at Allergan, Inc. Dr. Beddingfield also served as Chief Medical Officer of Allergan Medical and led the development of premier products in the dermatology and aesthetics industry, including KYBELLA®, BOTOX® Cosmetic, JUVEDERM XC®, VOLUMA XC®, LATISSE®, and NATRELLE® Breast Implants, all market-leading aesthetic treatments in their respective categories. During his tenure at Allergan, Dr. Beddingfield also led programs in acne, rosacea, scarring, hyperhidrosis, and hair loss. Dr. Beddingfield earned an MD degree with Honors from the University of North Carolina and a PhD in Policy Analysis from RAND Graduate School of Policy Studies, while simultaneously completing his Dermatology residency and Dermatologic Surgery fellowship at UCLA in the STAR program. He was the recipient of the Elle Genius Award in 2009. Currently, Dr. Beddingfield is a Clinical Associate Professor of Medicine/Dermatology at the UCLA School of Medicine where he has been on the faculty teaching and seeing patients since 2003. He serves on the Board of Directors of Advancing Innovation in Dermatology and is a founder of the Dermatology Summit and Dermatology Entrepreneurship Conferences. He also serves on the Board of Directors for Camp Wonder, a camp for children with severe skin diseases as well as the Board of Directors of Cytrellis, Inc. an aesthetic medical device company.

John Smither

Mr. John W. Smither is Chief Financial Officer of the Company, effective April 16, 2018. He previously served as the Company’s Chief Financial Officer from January 2016 through March 2017, and has served as an independent consultant in the biopharmaceutical industry. Mr. Smither served as Chief Financial Officer of Kythera Biopharmaceuticals, Inc., a publicly traded biotechnology company, from November 2007 until it was acquired by Allergan plc. in October 2015. From 1998 to 2007, Mr. Smither held various positions at Amgen Inc., a publicly traded biotechnology company, including Executive Director of Corporate Accounting, Vice President of Finance and Administration of Amgen’s European Division, and Head of Internal Audit. Prior to joining Amgen, Mr. Smither served as an Audit Partner at Ernst & Young LLP, a public accounting firm. Mr. Smither is a member of the board of directors of Achaogen, Inc., a publicly traded biopharmaceutical company, and serves as chair of the audit committee and a member of the compensation committee. Mr. Smither holds a B.S. in Business Administration from California State University, Los Angeles. Mr. Smither is a Certified Public Accountant (inactive) and a member of the American Institute of Certified Public Accountants, the California Society of Certified Public Accountants and Financial Executives International.

Majed Kheir

Mr. Majed Kheir is a Vice President - Operations of the company. Kheir served as Executive Director Supply Chain and Planning at Kythera Biopharmaceuticals, Inc. from 2012 to late 2015. Mr. Kheir also served as Kythera’s Head of Integration during Allergan’s $2.1B acquisition. Prior to that, Mr. Kheir held various positions at Amgen Inc., a biotechnology company. From 2009 to 2012, Mr. Kheir led corporate initiatives as Director Operations Strategic Planning, including optimization of Amgen’s manufacturing network, reduction in supply risk, global product allocation strategy and pipeline supply strategies. In 2010, Mr. Kheir established the business case that led to Amgen’s acquisition of its Ireland manufacturing facility from Pfizer, and served in a leadership role during the acquisition and site integration. From 2003 to 2009, Mr. Kheir held both strategic and technical roles in Drug Product Process Development and Strategic Resource Planning. Prior to Amgen, Mr. Kheir held various packaging engineering positions of increasing responsibility at Kimberly-Clark Corp. Mr. Kheir received an MBA from the Anderson School of Management at the University of California, Los Angeles and a BS in Packaging from Michigan State University.

Susan Lundeen

Ms. Susan Lundeen is a Vice President - Human Resources of the Company. from October, 2006 until it was acquired by Allergan in October, 2015. Ms. Lundeen was responsible for designing people systems, decision-making processes and cultural initiatives to grow the company from a privately held, start-up to a public, commercial organization. From September 2005 to June 2007, Ms. Lundeen was Vice President of Human Resources and Administration at Activus Healthcare Solutions, Inc., a healthcare distribution company. Prior to that experience, from February 1993 to September 2005, Ms. Lundeen held various positions at Amgen and ultimately served as Senior Director of Human Resources responsible for Strategic Sourcing and Staffing. Ms. Lundeen received a BA in Psychology and Business Administration from California Lutheran University and currently chairs the Board of Regents for California Lutheran University.

Caroline Van Hove

Ms. Caroline Van Hove is Chief Commercial Officer of the Company. Ms. Van Hove joins Sienna as a global leader with 20 years of diverse experience in the pharmaceutical, consumer and medical device industry, managing sales and marketing, commercial excellence, public relations and corporate affairs functions. Her global agency and large healthcare company experience spans North America to Europe, Africa, the Middle East to Asia Pacific and Latin America. Most recently, Ms. Van Hove served as senior vice president of international strategic marketing at Allergan, where she oversaw commercial operations for the medical aesthetics, eye care and specialty care franchises, including portfolio development. Previously, Ms. Van Hove held a series of escalating sales-and-marketing and corporate positions, starting in public relations, supporting the organization through several high-profile crises and issues, acquisitions and company milestones. She managed commercial operations in Europe, Africa and the Middle East, led Allergan's international medical aesthetics operations, drove many of the company's key acquisitions and integrations and helped establish a new international operating model for its medical aesthetics, ophthalmology and specialty care business. Ms. Van Hove also served as part of Allergan's Global Operating & International Leadership Teams. She holds an Executive Master of Business Administration from the Kellogg School of Management at Northwestern University, as well as bachelor's degrees in journalism from the University of Central Florida and in modern linguistics from the University of Antwerp.

James Hindman

Mr. James M. Hindman is Director of the Company. Mr. Hindman, served at Allergan, Inc., a multi-specialty healthcare company, from 1984 to March 2015, where he held positions of increasing responsibility, and most recently served as its Executive Vice President and Chief Financial Officer. From 2002 to August 2014, he served as Senior Vice President of Treasury, Risk and Investor Relations, and, from 1984 to 2002, served a variety of other finance positions at Allergan Inc., including Senior Vice President, Finance and Controller, Vice President, Finance, Vice President, Financial Planning and Analysis, and Assistant Corporate Controller. Mr. Hindman has served on the board of Millendo Therapeutics, Inc., a private biotechnology company, since June 2016. He has also provided financial consulting services to Cidara Therapeutics Inc., a public biotechnology company, since July 2015, and to RANI Therapeutics, a privately held biotechnology company, since December 2017. Mr. Hindman has served as a member of the Board of Regents at Loyola Marymount University since June 2015 and served on their Accounting Advisory Board from 2007 to June 2015. Mr. Hindman served as a member of the board of directors of The Allergan Foundation, a private charitable foundation, from 2009 to December 2015. He received a B.S. in Accounting from Loyola Marymount University, an M.B.A. from Pepperdine University, and is a Certified Public Accountant (inactive). Mr. Hindman was selected as a director because of his significant financial experience in the life sciences industry.

Robert More

Mr. Robert More is a Director of the Company. More joined Sienna Labs as Chairman of the Board in May 2013. He brings over 20 years of life sciences investing experience. Most recently, he was a Senior Advisor for Bill and Melinda Gates Foundation and led the “Global Health Venture Initiative.” Previously, he was a General Partner with Frazier Healthcare Ventures and Domain Associates. Bob managed successful investments in and served on the boards of ESP Pharma (acquired by Protein Design Labs, Inc.), Proxima Therapeutics (acquired by Cytyc Corporation), NovaCardia (acquired by Merck), Esprit Pharma (acquired by Allergan), IntraLase (acquired by Advanced Medical Optics, Inc.), Oceana Therapeutics (acquired by Salix Pharmaceuticals), Achaogen (NASDAQ: AKAO), Neothetics, (NASDAQ: NEOT) and Glaukos Corporation (NYSE: GLKS). Bob was also an investor in Clovis Pharmaceuticals, Affinivax, and Sienna Labs. He was a founding Board member of the Kauffman Fellows Program and serves on the boards of One Revolution and The Foundation for Innovative New Diagnostics (FIND). He received his B.A. from Middlebury College and an M.B.A. from the Darden School of Business Administration at the University of Virginia.